CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
Abstract Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since bexarotene reduces the expression of CCR4 in CTCL cells and CCL22 to decrease serum CCL22 levels, bexarotene inhibits t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Skin Health and Disease |
| Online Access: | https://doi.org/10.1002/ski2.222 |
| _version_ | 1797814338364375040 |
|---|---|
| author | Jun Yamamoto Kentaro Ohuchi Ryo Amagai Yuna Roh Junko Endo Hiromu Chiba Erika Tamabuchi Yumi Kambayashi Akira Hashimoto Yoshihide Asano Taku Fujimura |
| author_facet | Jun Yamamoto Kentaro Ohuchi Ryo Amagai Yuna Roh Junko Endo Hiromu Chiba Erika Tamabuchi Yumi Kambayashi Akira Hashimoto Yoshihide Asano Taku Fujimura |
| author_sort | Jun Yamamoto |
| collection | DOAJ |
| description | Abstract Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since bexarotene reduces the expression of CCR4 in CTCL cells and CCL22 to decrease serum CCL22 levels, bexarotene inhibits the migration of CTCL cells, as well as other CCR4+ cells, such as cytotoxic T cells and regulatory T cells, in the lesional skin of CTCL. In this report, the efficacy of bexarotene in 28 cases of CTCL, as well as its correlations with immunohistochemical profiles of tumour‐infiltrating leucocytes (TILs), was retrospectively investigated. The overall response rate at 1 and 4 months for the total cohort was 70.8% (95% CI, 50.6%–86.3%) and 47.8% (95% CI, 29.2%–67.0%), respectively. The disease control rate for the total cohort at 4 months was 65.2% (95% CI, 44.8%–81.3%). The mean event‐free survival for all patients was 4.1 months (0.3–68.5 months). In addition, the immunoreactive cells were calculated using digital microscopy, suggesting that the ratio of CD25+ cells among TILs was significantly increased in patients who responded to bexarotene (p = 0.0209), whereas there were no significant differences in the ratios of CD8+ cells, granulysin+ cells, and Foxp3+ cells among TILs between responder and non‐responder patients. Collectively, the ratio of CD25 expression among TILs might be a predictive biomarker for the efficacy of bexarotene. |
| first_indexed | 2024-03-13T08:06:12Z |
| format | Article |
| id | doaj.art-52865415f3a44a4aba73952b35698b8d |
| institution | Directory Open Access Journal |
| issn | 2690-442X |
| language | English |
| last_indexed | 2024-03-13T08:06:12Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Skin Health and Disease |
| spelling | doaj.art-52865415f3a44a4aba73952b35698b8d2023-06-01T05:13:40ZengWileySkin Health and Disease2690-442X2023-06-0133n/an/a10.1002/ski2.222CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomasJun Yamamoto0Kentaro Ohuchi1Ryo Amagai2Yuna Roh3Junko Endo4Hiromu Chiba5Erika Tamabuchi6Yumi Kambayashi7Akira Hashimoto8Yoshihide Asano9Taku Fujimura10Department of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanDepartment of Dermatology Tohoku University Graduate School of Medicine Sendai JapanAbstract Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since bexarotene reduces the expression of CCR4 in CTCL cells and CCL22 to decrease serum CCL22 levels, bexarotene inhibits the migration of CTCL cells, as well as other CCR4+ cells, such as cytotoxic T cells and regulatory T cells, in the lesional skin of CTCL. In this report, the efficacy of bexarotene in 28 cases of CTCL, as well as its correlations with immunohistochemical profiles of tumour‐infiltrating leucocytes (TILs), was retrospectively investigated. The overall response rate at 1 and 4 months for the total cohort was 70.8% (95% CI, 50.6%–86.3%) and 47.8% (95% CI, 29.2%–67.0%), respectively. The disease control rate for the total cohort at 4 months was 65.2% (95% CI, 44.8%–81.3%). The mean event‐free survival for all patients was 4.1 months (0.3–68.5 months). In addition, the immunoreactive cells were calculated using digital microscopy, suggesting that the ratio of CD25+ cells among TILs was significantly increased in patients who responded to bexarotene (p = 0.0209), whereas there were no significant differences in the ratios of CD8+ cells, granulysin+ cells, and Foxp3+ cells among TILs between responder and non‐responder patients. Collectively, the ratio of CD25 expression among TILs might be a predictive biomarker for the efficacy of bexarotene.https://doi.org/10.1002/ski2.222 |
| spellingShingle | Jun Yamamoto Kentaro Ohuchi Ryo Amagai Yuna Roh Junko Endo Hiromu Chiba Erika Tamabuchi Yumi Kambayashi Akira Hashimoto Yoshihide Asano Taku Fujimura CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas Skin Health and Disease |
| title | CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas |
| title_full | CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas |
| title_fullStr | CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas |
| title_full_unstemmed | CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas |
| title_short | CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas |
| title_sort | cd25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous t cell lymphomas |
| url | https://doi.org/10.1002/ski2.222 |
| work_keys_str_mv | AT junyamamoto cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT kentaroohuchi cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT ryoamagai cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT yunaroh cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT junkoendo cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT hiromuchiba cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT erikatamabuchi cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT yumikambayashi cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT akirahashimoto cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT yoshihideasano cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas AT takufujimura cd25expressioncouldbeaprognosticmarkerofbexarotenemonotherapyforcutaneoustcelllymphomas |